Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: The Company manufactures and distributes apparatus, instruments, and consumables for life science research. Operations are focused on the Apparatus and Instrumentation Business segment. The Capital Equipment Business segment is reported as discontinued operations pending divestiture.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2008 |
|---|---|---|
| Revenues (Continuing Ops) | $23,049 | $45,008 |
| Gross Profit | $10,763 | $21,088 |
| Gross Margin % | 46.7% | 46.9% |
| Operating Income | $1,474 | $3,040 |
| Net Loss (Total) | $(2,206) | $(1,519) |
| Cash and Cash Equivalents | $13,800 (Continuing Ops) | $14,205 (Total) |
| Long-Term Debt | $88 | $88 |
| Revolving Credit Facility Usage | $0 | $0 |
Note: Net Loss includes significant losses from discontinued operations ($3.3M for Q2; $3.8M for YTD). Income from continuing operations was $1.1M for Q2 and $2.3M for YTD.
Material Changes vs. Prior Period
- Revenue Growth: Revenues from continuing operations increased 12.9% ($2.6M) in Q2 and 13.9% ($5.5M) YTD compared to 2007. Growth was driven by the acquisition of Panlab ($2.8M in Q2; $5.2M YTD) and increased sales of the new microliter spectrophotometer.
- Margin Compression: Gross margin decreased to 46.7% in Q2 (from 48.9% in 2007) and 46.9% YTD (from 49.1% in 2007). This decline is attributed to Panlab's lower-margin product mix (higher proportion of distributed vs. manufactured goods) and inventory write-downs related to restructuring.
- Restructuring Charges: The Company recorded $0.9M in restructuring charges in Q2 2008 (totaling $1.8M for the first half of 2008) to consolidate business functions, including severance and facility closure costs.
- Discontinued Operations: A $2.9M asset impairment charge was recorded in Q2 2008 related to the remaining assets of the Capital Equipment Business segment held for sale.
Guidance, Outlook, and Risks
- Strategic Initiatives: Management outlined five initiatives for 2008, including the launch of a new Harvard Apparatus catalog, Panlab product expansion in the US, a new distribution contract with GE Healthcare, and new 2-D electrophoresis products. Progress has been made, though uptake of new electrophoresis products has been slower than expected.
- Liquidity: The Company holds $13.8M in cash from continuing operations and has a $20.0M revolving credit facility with no outstanding balance. Management expects current resources to be sufficient for operations for 12 months and beyond.
- Divestiture Risk: The sale of the remaining Capital Equipment Business segment requires lender consent. Failure to obtain consent could trigger a default under the credit facility, potentially accelerating indebtedness.
- Foreign Currency: Approximately 62% of revenues are derived from non-U.S. operations. The Company does not currently hedge foreign currency exposure, making results sensitive to exchange rate fluctuations (specifically the Euro and British Pound).
Investor Verification Checklist
- Discontinued Operations: Verify the timeline and potential proceeds from the sale of the remaining Capital Equipment Business segment (Union Biometrica product lines).
- Restructuring Execution: Monitor the completion of consolidation initiatives (Hoefer and Asys Hitech) and the realization of expected cost savings.
- GE Healthcare Contract: Assess the impact of the new exclusive distribution agreement with GE Healthcare on future revenue stability and margins.
- Debt Covenants: Confirm compliance with financial covenants, particularly regarding the requirement for lender consent prior to the divestiture of remaining discontinued assets.
- Inventory Valuation: Review future inventory write-down risks associated with the consolidation of product lines and technological changes.